Targeted therapy for melanoma: is double hitting a home run?

KSM Smalley, VK Sondak - Nature Reviews Clinical Oncology, 2013 - nature.com
A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK
inhibitors with BRAF inhibition alone showed increased progression-free survival and …
被引用次数：13 相关文章

Targeted therapy for melanoma: is double hitting a home run?

KS Smalley, VK Sondak - Nature reviews. Clinical Oncology, 2012 - europepmc.org
A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK
inhibitors with BRAF inhibition alone showed increased progression-free survival and …

Targeted therapy for melanoma: is double hitting a home run?

KSM Smalley, VK Sondak - Nature Reviews Clinical Oncology, 2013 - go.gale.com
A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK
inhibitors with BRAF inhibition alone showed increased progression-free survival and …

Targeted therapy for melanoma: is double hitting a home run?

KSM Smalley, VK Sondak - Nature reviews. Clinical …, 2013 - pubmed.ncbi.nlm.nih.gov
A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK
inhibitors with BRAF inhibition alone showed increased progression-free survival and …

[引用][C] Skin cancer: Targeted therapy for melanoma: is double hitting a home run?

KSM Smalley, VK Sondak - Nature Reviews. Clinical …, 2013 - Nature Publishing Group